Press – Mineralys Therapeutics, Inc.

November 16, 2022

Mineralys Therapeutics Announces Positive Topline Phase 2 Data for MLS-101…

“We are very pleased to report that the Target-HTN trial met its primary and secondary endpoints, with MLS-101 demonstrating substantial placebo-adjusted reduction…

Mineralys Therapeutics Closes $118 Million Oversubscribed Series B Financing…

Mineralys Therapeutics, Inc., a private, clinical-stage biopharmaceutical company committed to developing a best-in-class, novel therapy for the treatment of hypertension,…

Mineralys Therapeutics Appoints Adam Levy as Chief Financial Officer…

“We are pleased to announce Adam’s appointment and welcome him to the Mineralys leadership team. His extensive corporate finance experience in the life sciences sector…

Mineralys Therapeutics Closes $40 Million Series A Funding

Mineralys Therapeutics, a private, clinical-stage biopharmaceutical company founded by Catalys Pacific, announced today that the Company…